Kanserli Çocuklarda Kemoterapi ile İlişkili Gecikmiş Bulantı ve Kusma

Year 2011, Volume: 9 Issue: 2, 1 - 6, 01.09.2011

Metin Demirkaya Betül Sevinir Ramazan Özdemir Meliha Demiral

Abstract

Giriş: Çocuk onkoloji hastalarında kemoterapi ile ilişkili gecikmiş bulantı ve kusmanıninsidansı ve ilişkili faktörler araştırıldı.Gereç ve Yöntem: Çalışmaya Ocak-Aralık 2009 tarihleri arasında, 0-18 yaş arası, lenfoma ve solid tümörlü, kemoterapi alan hastalar dâhil edildi. Hastaların kusmaları sayıolarak, bulantı şiddetleri ise 0-10 arası rakamsal ölçme yöntemi ile derecelendirildi.Bulantı şiddeti ve kusma sayıları günlük olarak aynı hekim tarafından kaydedildi. Bulgular: Çalışmada 35 hastada, 69 kemoterapi kürü sonrası gecikmiş bulantı ve kusmaatağı incelendi. Hastaların 22’si kız, 13’ü erkek; yaş ortalaması 8,88±5,43 yıl yaş aralığı1-17 yıl idi. Hastalarda gecikmiş bulantı varlığı 1. gün %2,8, 2. gün %81,1, 3. gün %68,1,4. gün %46,3, 5. gün %24,6; gecikmiş kusma varlığı ise 1. gün %1,4, 2. gün %65,2, 3. gün%43,5, 4. gün %24,6, 5. gün %13,0 oranında idi. Cinsiyetler arasında gecikmiş bulantışiddeti ve kusma sayısı açısından fark saptanmadı. Yaş ile gecikmiş bulantı şiddetiarasında 2, 3, 4 ve 5. günlerde istatistiksel olarak anlamlı pozitif korelasyon mevcuttu korelasyon katsayısı sırasıyla; 0,29, 0,27, 0,33, 0,24; p değeri sırasıyla; =0,013, =0,023,=0,005, =0,046 . İlaçların emetojenite derecesinin kusma sayısı ve bulantı şiddetineistatistiksel olarak anlamlı etkisi saptanmadı. Sisplatinli kemoterapi protokolü alanlarda kusma sayısı ikinci ve üçüncü günlerde; bulantı şiddeti birinci, ikinci ve üçüncü günlerde istatistiksel olarak anlamlı olacak şekilde fazla idi.Sonuç: Çalışmamızda bulantı ve kusmanın en yüksek oranda ikinci gün var olduğu,sisplatin alan hasta grubunda kusma sayısı ve bulantı şiddetinin daha fazla olduğu veyaşla bulantı şiddetinin pozitif korelasyon gösterdiği saptandı

Keywords

Gecikmiş bulantı ve kusma, çocukluk çağı kanserleri, kemoterapi

Delayed Chemotherapy-Induced Nausea and Vomiting in Children with Cancer

Abstract

Introduction: The incidence of chemotherapy-induced late emesis and vomiting in pediatric oncology patients and the related factors were investigated. Materials and Method: The study consisted of the patients aged between 0-18 yearsand given chemotherapy between January and December 2009. The amount of vomiting was described on numbers and the grade of nausea was describedbetween 0-10. Vomiting and nausea was evaluated daily by the same clinician. Results: Sixty nine late nausea and vomiting episodes in 35 patients were evaluated.There were 22 females and 13 males in the study group. Mean age was 8.88±5.43 1to 17 years. Late nausea was found 2.8% on the first day, 81.1% on the second day,68% on the third day, 46.3% on the fourth day and 24.6% on the fifth day. Late emesiswas found 1.4% on the first day, 65.2% on the second day, 43.5% on the third day,24.6% on the fourth day and 13% on the fifth day. There was no significant differencein nausea and emesis between boys and girls. There was a positive correlationbetween the age and nausea/emesis episodes. The correlation coefficients betweenage and nausea grade on 2, 3, 4 and 5thdays were 0.29, 0.27, 0.33, and 0.24, respectively; and p values were 0.013, 0.023, 0.005 and 0.046, respectively. The degreeDemirkaya ve ark. Kanserli Çocuklarda Geçikmiş Bulantı ve Kusmaof the emetogenic potential of drugs on the number of emesis and the severity of nausea was found to be not significant.The vomiting was statistically significant on second and third days and grade of nausea on first, second and third days inthe patients given cisplatin.Conclusion: In this study, it was found that emesis was most seen in the second day of chemotherapy, the grade of vomiting was higher in patients receiving cisplatin and there is a positive correlation between age and grade of nausea

Keywords

Nausea, vomiting, child, cancer, chemotherapy

References

• 1. Roila F, Donati D, Tamberi S, Margutti G. Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer 2002;10:88-95.
• 2. Lohr L. Chemotherapy-induced nausea and vomiting. Cancer J 2008;14:85-93.
• 3. Jordan K, Kasper C, Schmoll HJ. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment. Eur J Cancer 2005;41:199-205.
• 4. Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol 2008;5:32-43.
• 5. Antonarakis ES, Hain RD. Nausea and vomiting associated with cancer chemotherapy: drug management in theory and in practice. Arch Dis Child 2004;89:877-80.
• 6. Lindley C, Goodin S, McCune J, Kane M, Amamoo MA, Shord S et al. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy comparison of ondansetron, prochlorperazine, and dexamethasone. Am J Clin Oncol 2005;28:270-6.
• 7. Dupuis LL, Lau R, Greenberg ML. Delayed nausea and vomiting in children receiving antineoplastics. Med Pediatr Oncol 2001;37:115-21.
• 8. Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: Past, present, and future recommendations. Oncologist 2007;12:1143-50.
• 9. LeBaron S, Zeltzer LK, LeBaron C, Scott SE, Zeltzer PM. Chemotherapy side effects in paediatric oncology patients: drugs, age, and sex as risk factors. Med Pediatr Oncol 1988;16:263-8.
• 10. Kris MG, Roila F, De Mulder PH, Marty M. Delayed emesis following anticancer chemotherapy. Support Care Cancer 1998;6:228-32.
• 11. Holdsworth MT, Raisch DW, Frost J. Acute and delayed nausea and emesis control in pediatric oncology patients. Cancer 2006;106:931-40.
• 12. Kris MG, Gralla RJ, Clark RA, Tyson LB, O'Connell JP, Wertheim MS et al. Incidence, course and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985;3:1379-84.
• 13. Passalacqua R, Cocconi G, Bella M, Monici L, Michiara M, Bandini N et al. Double-blind, randomized trial for the control of delayed emesis in patients receiving cisplatin: comparison of placebo vs adrenocorticotropic hormone (ACTH). Ann Oncol 1992;3:481-5.
• 14. Shinkai T, Saijo N, Eguchi K, Sasaki Y, Tamura T, Fujiwara Y et al. Control of cisplatin-induced delayed emesis with metoclopramide and dexamethasone: a randomized controlled trial. Jpn J Clin Oncol 1989;19:40-4.
• 15. Roila F, Boschetti E, Tonato M, Basurto C, Bracarda S, Picciafuoco M et al. Predictive factors of delayed emesis in cisplatin-treated patients and tolerability of metoclopramide or dexamethasone: A randomized single-blind study. Am J Clin Oncol 1991;14:238-42.
• 16. Gandara DR, Harvey WH, Monaghan GG, Perez EA, Stokes C, Bryson JC et al. The delayed emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. Semin Oncol 1992;19:67-71.
• 17. Kris MG, Gralla RJ, Tyson LB, Clark RA, Cirrincione C, Groshen S. Controlling delayed vomiting: double-blind randomized trial comparing placebo, dexamethasone alone and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989;7:108-14.
• 18. Delayed emesis induced by moderately emetogenic chemotherapy: do we need to treat all patients? The Italian Group for Antiemetic Research. Ann Oncol 1997:8:561-7.
• 19. Foot AB, Hayes C. Audit of guidelines for effective control of chemotherapy and radiotherapy induced emesis. Arch Dis Child 1994;71:475-80.
• 20. Pinkerton CR, Williams D, Wootton C, Meller ST, McElwain TJ. 5-HT3 antagonist ondansetron-an effective outpatient antiemetic in cancer treatment. Arch Dis Child 1990;65:822-5.
• 21. Dick GS, Meller ST, Pinkerton CR. Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis. Arch Dis Child 1995;73:243-5.
• 22. Robinson DL, Carr BA. Delayed vomiting in children with cancer after receiving moderately high or highly emetogenic chemotherapy. J Pediatr Oncol Nurs 2007;24:70-80.
• 23. Berrak SG, Ozdemir N, Bakirci N, Turkkan E, Canpolat C, Beker B et al. A double-blind, crossover, randomized dose-comparison trial of granisetron for the prevention of acute and delayed nausea and emesis in children receiving moderately emetogenic carboplatin-based chemotherapy. Support Care Cancer 2007;15:1163-8.
• 24. Berberoglu S. Prevention of emesis by tropisetron in children receiving combined chemotherapy with cisplatin. Pediatr Hematol Oncol 1995;12:479-83.
• 25. Kandemir EG, Türken O, Önde ME, Yaylacı M, Çankır Z, Top C et al. Sisplatine bağlı gecikmiş emezisin kontrolünde akut emezisin başarılı kontrolünün rolü ve dekzametazon ile ondansetron artı dekzametazon' un karşılaştırılması. Gülhane Tıp Dergisi 1999;41:278-82.
• 26. Görgün Ö, Kebudi R, Ayan ı. Çocuklarda kombine kanser kemoterapisine bağlı bulantı ve kusmanın önlenmesinde tropisetron. Türk Onkoloji Dergisi 2001;16:7-12.
• 27. Tanındı ş, Köseoğlu V, Kürekçi AE, Akın R, Özcan O. Çocuklarda, kemoterapiye bağlı kusma ataklarında, ondansetron ve metoclopramide + diphenhydramine'in etki ve yan etkiler yönünden karşılaştırılması. Türk Onkoloji Dergisi 1995;10:9-14.
• 28. Özkan A, Yıldız ı, Yüksel L, Apak H, Celkan T. Çocuklarda kombine kanser kemoterapisine bağlı bulantı ve kusmanın önlenmesinde tropisetron. Türk Onkoloji Dergisi 1999;14:23-7.
• 29. Uysal KM, Olgun N, Sarıalioğlu F. Tropisetron in the prevention of chemotherapy-induced acute emesis in pediatric patients. Turk J Pediatr 1999;41:207-18.